A Phase 2 Study Comparing TAS-102 Versus Topotecan or Amrubicin to Treat Small Cell Lung Cancer Following Platinum-Based Chemotherapy
Stopped The preliminary data does not suggest any safety signal, but an ad hoc interim analysis showed an imbalance of PFS between the two arms
Conditions
- Small Cell Lung Cancer (SCLC)
Interventions
- DRUG: TAS-102
- DRUG: Amrubicin (Japan)
- DRUG: Topotecan (Japan/Europe)
Sponsor
Taiho Oncology, Inc.
Collaborators